Aim:　We　conducted　network　meta-analysis　to　assess　cardiovascular　toxicity　of　anaplastic　lymphoma　kinase-tyrosine　kinase　inhibitors　(ALK-TKIs).　Materials　&　methods:　Eleven　articles　involving　2855　patients　and　six　interventions　including　crizotinib,　alectinib,　ceritinib,　lorlatinib,　brigatinib　and　chemotherapy　were　analyzed.　Results:　No　significant　difference　was　observed　in　overall　cardiovascular　risk　among　ALK-TKIs.　Subgroup　analysis　showed　that　for　cardiac　toxicity,　crizotinib　and　alectinib　were　more　likely　to　cause　myocardial　rhythm　abnormalities.　Crizotinib　and　ceritinib　had　a　higher　risk　of　Q-T　prolongation　than　chemotherapy.　For　vascular　toxicity,　crizotinib　and　ceritinib　had　a　higher　risk　of　thrombotic　events　than　brigatinib.　Crizotinib　and　lorlatinib　were　more　likely　to　cause　blood　pressure　abnormalities.　Conclusion:　Clinicians　should　carefully　monitoring　cardiovascular　events　when　ALK-TKIs　used　in　NSCLCs　patients　with　baseline　cardiovascular　diseases.　©　2024　Informa　UK　Limited,　trading　as　Taylor　&　Francis　Group.